[go: up one dir, main page]

MA46266A - CRYSTALLINE FORMS - Google Patents

CRYSTALLINE FORMS

Info

Publication number
MA46266A
MA46266A MA046266A MA46266A MA46266A MA 46266 A MA46266 A MA 46266A MA 046266 A MA046266 A MA 046266A MA 46266 A MA46266 A MA 46266A MA 46266 A MA46266 A MA 46266A
Authority
MA
Morocco
Prior art keywords
crystalline forms
crystalline
forms
Prior art date
Application number
MA046266A
Other languages
French (fr)
Other versions
MA46266B1 (en
Inventor
Daniel Leuenberger
Stefan Reber
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA46266A publication Critical patent/MA46266A/en
Publication of MA46266B1 publication Critical patent/MA46266B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA46266A 2016-09-22 2017-09-21 Crystal forms MA46266B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2016072562 2016-09-22
PCT/EP2017/073858 WO2018055016A1 (en) 2016-09-22 2017-09-21 Crystalline forms

Publications (2)

Publication Number Publication Date
MA46266A true MA46266A (en) 2019-07-31
MA46266B1 MA46266B1 (en) 2022-02-28

Family

ID=59923448

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46266A MA46266B1 (en) 2016-09-22 2017-09-21 Crystal forms

Country Status (28)

Country Link
US (3) US10730896B2 (en)
EP (2) EP3981774A1 (en)
JP (1) JP7097369B2 (en)
KR (1) KR102552795B1 (en)
CN (1) CN109715639B (en)
AU (1) AU2017331930B2 (en)
BR (1) BR112019004845A2 (en)
CA (1) CA3037794A1 (en)
CL (1) CL2019000728A1 (en)
CY (1) CY1125052T1 (en)
DK (1) DK3515924T3 (en)
EA (1) EA201990723A1 (en)
ES (1) ES2908572T3 (en)
HR (1) HRP20220234T1 (en)
HU (1) HUE057772T2 (en)
IL (1) IL265445B2 (en)
LT (1) LT3515924T (en)
MA (1) MA46266B1 (en)
MX (1) MX2019003093A (en)
MY (1) MY193080A (en)
PH (1) PH12019500567B1 (en)
PL (1) PL3515924T3 (en)
PT (1) PT3515924T (en)
RS (1) RS62946B1 (en)
SI (1) SI3515924T1 (en)
TW (1) TWI752086B (en)
UA (1) UA124073C2 (en)
WO (1) WO2018055016A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331930B2 (en) 2016-09-22 2021-07-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (en) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
US20240317784A1 (en) 2021-07-13 2024-09-26 Viatris Asia Pacific Pte. Ltd. Process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
US6855715B1 (en) 1999-06-14 2005-02-15 Eli Lilly And Company Serine protease inhibitors
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
NZ540872A (en) 2002-12-11 2007-08-31 Schering Ag 2-Aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
BRPI0409255A (en) 2003-04-09 2006-03-28 Wyeth Corp 2- (8,9-dioxo-2,6-diazabi-cyclo (5.2.0) non-1 (7) -en-2-yl) alkylphosphonic acid derivatives and their use as d-aspartic receptor antagonists -n-methyl (nmda)
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
AU2006305538B2 (en) 2005-10-21 2012-06-28 Idorsia Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
AR063258A1 (en) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd DERIVATIVES OF 2-AMINOCARBONIL-PYRIDINE, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
AR063518A1 (en) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd DERIVATIVES 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT AND / OR PREVENT VISCERAL, HEPATIC AND RENAL PERIPHERAL VASCULAR DISEASES, CARDIOVASCULAR DISEASES AND CEREBROVASCULAR DISEASES ASSOCIATED WITH THE ADJUSTMENT OF PLATELETS, INCLUDING THROMBOS
JP4785881B2 (en) 2007-02-27 2011-10-05 大塚製薬株式会社 Medicine
JP5309131B2 (en) 2007-04-23 2013-10-09 サノフイ Quinoline-carboxamide derivatives as P2Y12 antagonists
EP2225253B1 (en) 2007-11-29 2012-06-27 Actelion Pharmaceuticals Ltd. Phosphonic acid derivates and their use as p2y12 receptor antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
AR071652A1 (en) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd DERIVATIVES 2- SUBSTITUTED PHENYL-PYRIDINE
AR071653A1 (en) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd DERIVATIVES 2-FENIL-4-CICLOPROPIL-PYRIMIDINE
AU2010233378A1 (en) 2009-04-08 2011-11-24 Actelion Pharmaceuticals Ltd. 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as ADP receptor antagonists
NZ596388A (en) 2009-04-22 2013-05-31 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
AU2017331930B2 (en) 2016-09-22 2021-07-15 Idorsia Pharmaceuticals Ltd Crystalline forms
MA49887A (en) 2017-03-15 2020-06-24 Idorsia Pharmaceuticals Ltd SUBCUTANEOUS ADMINISTRATION OF A P2Y12 RECEPTOR ANTAGONIST
WO2022013276A1 (en) 2020-07-15 2022-01-20 Idorsia Pharmaceuticals Ltd Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Also Published As

Publication number Publication date
PT3515924T (en) 2022-03-11
CA3037794A1 (en) 2018-03-29
HRP20220234T1 (en) 2022-05-13
CY1125052T1 (en) 2024-02-16
LT3515924T (en) 2022-03-10
UA124073C2 (en) 2021-07-14
EP3981774A1 (en) 2022-04-13
KR102552795B1 (en) 2023-07-06
US12227532B2 (en) 2025-02-18
AU2017331930A1 (en) 2019-03-07
MY193080A (en) 2022-09-26
IL265445A (en) 2019-05-30
NZ750772A (en) 2023-10-27
PH12019500567A1 (en) 2019-11-18
US11365209B2 (en) 2022-06-21
US20210009614A1 (en) 2021-01-14
SI3515924T1 (en) 2022-04-29
JP2019529553A (en) 2019-10-17
MX2019003093A (en) 2019-07-18
TW201813965A (en) 2018-04-16
MA46266B1 (en) 2022-02-28
CN109715639B (en) 2022-04-19
DK3515924T3 (en) 2022-03-21
EP3515924A1 (en) 2019-07-31
BR112019004845A2 (en) 2019-06-04
KR20190052704A (en) 2019-05-16
TWI752086B (en) 2022-01-11
IL265445B2 (en) 2024-05-01
RS62946B1 (en) 2022-03-31
PH12019500567B1 (en) 2024-01-31
IL265445B1 (en) 2024-01-01
PL3515924T3 (en) 2022-04-11
HUE057772T2 (en) 2022-06-28
ES2908572T3 (en) 2022-05-03
US10730896B2 (en) 2020-08-04
WO2018055016A1 (en) 2018-03-29
EP3515924B1 (en) 2021-12-15
CL2019000728A1 (en) 2019-07-05
JP7097369B2 (en) 2022-07-07
CN109715639A (en) 2019-05-03
US20200017534A1 (en) 2020-01-16
AU2017331930B2 (en) 2021-07-15
US20220275011A1 (en) 2022-09-01
EA201990723A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
MA47596A (en) CRYSTALLINE FORMS OF 4-PYRIMIDINESULFAMIDE APROCITENTAN
EP3609871A4 (en) ARYL-CYCLOPROPYL-AMINO-ISOCHINOLINYL-AMIDE COMPOUNDS
LT3978483T (en) CRYSTALLINE (S)-AFOXOLANER TOLUENE SOLVATE
PT3298027T (en) ANTELMINTHIC DEPSYPEPTIDE COMPOUNDS
PT4039675T (en) PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS
EP3435660A4 (en) MOUNTED
LT3464336T (en) COMPOUNDS
EP3227309A4 (en) DIFUCOSYLLACTOSE CRYSTALLINE
EP3390422A4 (en) CRYSTALLINE SHAPES OF LNT
HUE054351T2 (en) Compounds
LT3597189T (en) CRYSTALLINE COMPOUNDS
DK3819287T3 (en) AMORPHOUS TAPENTADOLPHOSPHATE
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE
MA46567A (en) ERAVACYCLINE CRYSTALLINE FORMS
MA46266A (en) CRYSTALLINE FORMS
LT3331885T (en) COMPOUNDS
EP3713941A4 (en) PYRAZOLOPYRIDINONE COMPOUNDS
EP3717483A4 (en) PYRAZOLOPYRIDINONE COMPOUNDS
DK3672941T3 (en) PYRIDYLPYRIDON COMPOUNDS
EP3491206A4 (en) IMPROVED SHUTTERING ARRANGEMENT
ES1159683Y (en) NEOVAGINAL PROTESIS
DK3672962T3 (en) MORPHOLINYLPYRIDONE COMPOUNDS
DE112017000296A5 (en) RADGESCHWINDIGKEITSSENSORVORRICHTUNG
DE102016001934A8 (en) Verdunster
MA52458A (en) NEW CRYSTALLINE FORMS